Ozempic had better Alzheimer's disease protective advantage in women, and in the special case of SGLT2-inhibitors, the Ozempic advantage was exclusive in women, with SGLT2 inhibitors outperforming Ozempic slightly by 14% in Alzheimer's disease.

This is very intriguing in light…